RE: New Contracts2 Dec 2021 11:44
Don’t forget most revenue is non DHSC like WHO who have stepped up big time
I’d expect increased orders from DHSC, WHO, UNICEF, Private Sector & other countries
They have a wider product portfolio also as per Half Year update:
· Rapid development and launch of 18 new assays to support laboratories, clinicians, and private testing for COVID-19 since the beginning of 2021
o Launch and continued expansion of PCR genotyping portfolio, SNPsig®, to detect variants of SARS-CoV-2, including VariPLEX™ to detect six key mutations in a single test
§ Portfolio included in the NHS England Framework for detecting Variants of Concern
o Expansion of PROmate® COVID-19 PCR portfolio for workflow efficiency in a near-to-patient setting
o Expansion of genesig® COVID-19 PCR portfolio
o Expansion of PathFlow® LFT portfolio with antibody and antigen tests for COVID-19
· Launch of VersaLab™ mobile processing laboratories and VersaLab™ Portable to expand near-patient testing opportunities in private sector testing
· Inclusion in PHE National Framework Agreement, resulting in a new contract with the DHSC for the supply of PROmate® COVID-19 tests to the NHS (post period)
· Secured new contracts with WHO and UNICEF for the supply of COVID-19 products
o Appointment of US General Manager and set-up of Novacyt US Inc